Ozempic is a sensation.
It melts away fat. It changes how people see themselves in mirrors. Semaglutide has worked wonders for millions trying to shed pounds.
But here’s the catch.
A new study says it still isn’t the most effective medical option on the table. In fact.
Evidence suggests the gap between these drugs and another form of intervention is not even close.
The Data Doesn’t Lie
New York University researchers ran the numbers in 2025.
They pitted surgery—sleeve gastrectomy and gastric bypass—against the heavy hitters of pharma: semaglutide and tirzepatide. These GLP-1 receptor agonists mimic natural hormones to crush appetite. They feel like magic in your brain.
The team used health records. They matched patients by age. Body mass index. Blood sugar. Fair fight.
The results were stark.
Surgery patients dropped 25.7 percent of their total body weight over two years. Drug users?
They lost 5.3 percent.
Why The Gap?
Is it just willpower?
Maybe. Many people ditch GLP-1s. Seventy percent stop taking them within a year. Surgery is harder to walk away from. It’s permanent. Or as permanent as it gets.
But even over shorter windows, the edge stayed with the knife.
“Clinical trials show 15 to 21 percent weight loss for GLP-1s,” noted Avery Brown, a NYU resident presenting the findings. “This study shows real-world loss is considerably lower.”
Patients need to adjust expectations. Or get on the table.
“GLP-1 patients may need to adhere more closely to treatment… or opt for metabolic and baratric surgery.”
Bias In The Room
Who funded this?
The American Society for Metabolic and Baratric Surgery (ASMBS). They certainly want surgery to look good. That’s a conflict. Keep it in mind.
Still, the researchers aren’t trashing the pills. Semaglutide helped people. Just… less than cutting.
Prescriptions are skyrocketing. Comparisons are necessary. Which option fits which body? That’s the question.
Ann M. Rogers, ASMBS President and uninvolved in the data collection, put it bluntly: surgery is more effective. More durable.
People love the drugs. They hate the needles after six months. Meanwhile, few eligible folks choose the operating room. Fear. Cost. Uncertainty.
It Isn’t Just Fat
Ozempic wasn’t born for weight loss.
It’s for diabetes. It lowers blood sugar. New hints suggest it might curb cancer risk too. Cardiovascular protection. Nice side effects.
But surgery controlled blood sugar better in this trial.
Doesn’t make pills obsolete. Just secondary for some outcomes.
Surgery isn’t a fix-all either. Invasive. Permanent. Demanding. You still have to eat right. You still have to move. The scar doesn’t do the work. You do.
Next Steps
Karan Chhabra, another NYU surgeon, looks ahead.
He wants to know why outcomes vary. Who is better served by pills versus scalpels? How do out-of-pocket costs derail progress?
These questions remain.
The research hit the ASMBS meeting in June 2024. The conversation continues.
Do we chase the high of rapid drug-induced loss? Or commit to the harsh reality of metabolic surgery?
Probably depends on you. And your wallet.
